Protective Function Testing of Health Foods Against Chemical-Induced Liver Injury: Methods, Standard

Health foods and dietary supplements that claim a protective effect against chemically induced liver injury must be substantiated through standardized scientific evaluation before such claims can be made or registered. This article explains the protective function test against chemical liver injury, including the animal models, biomarkers such as ALT and AST, testing protocols, applicable standards, and acceptance criteria used by accredited third-party laboratories. Understanding this evaluation process helps manufacturers meet regulatory requirements and bring credible hepatoprotective products to market.

Technical Overview

The protective function test against chemical liver injury is a standardized in vivo evaluation designed to verify whether a health food product can mitigate liver damage caused by hepatotoxic chemical agents. In many regulatory frameworks, particularly in China, "protection against chemical liver injury" is a recognized health function claim that requires scientific substantiation through animal experimentation prior to product registration or filing.

The core principle of the test is straightforward: liver injury is deliberately induced in laboratory animals using a well-characterized hepatotoxin, while the test sample is administered concurrently. If the treated animals exhibit significantly reduced liver damage compared with the injured control group—as evidenced by biochemical markers and histopathological examination—the product is considered to possess a protective function against chemical liver injury.

The evaluation is primarily conducted in accordance with the Technical Standards for Testing and Assessment of Health Food (2003 Edition) issued under the Chinese national health food evaluation framework, supplemented by the GB 15193 series national standards for food safety toxicological testing procedures and laboratory operation. Testing should be performed in laboratories accredited to ISO/IEC 17025 and compliant with Good Laboratory Practice (GLP) principles for animal studies.

Testing Samples

A wide range of health food and dietary supplement dosage forms can be evaluated for their protective effect against chemical liver injury. Typical sample categories submitted to accredited third-party laboratories include:

Common Sample Types

• Tablets, capsules, and softgels containing herbal or botanical extracts
• Oral liquids, tonic beverages, and fermented liquid preparations
• Granules, powders, and teabag-style formulations intended for dissolution
• Functional ingredients such as silymarin, kudzu root (Pueraria lobata) extract, schisandra chinensis extract, taurine, phosphatidylcholine (lecithin), and Ganoderma lucidum preparations
• Compound formulations combining traditional herbal ingredients with vitamins or amino acids

Sample Submission Requirements

• Samples should be the finished product in its final market form, or the representative pilot-scale batch intended for commercialization
• A sufficient quantity is required to cover the full dosing period (typically a 30-day animal feeding study) across multiple dose groups, plus reserve material
• Documentation should include the formula composition, recommended human daily intake, batch number, production date, shelf life, and physical-chemical properties relevant to dose preparation
• The sample must pass preliminary safety and hygiene testing, including microbial limits and contaminant screening, before functional evaluation begins

Testing Items

The evaluation integrates biochemical, gravimetric, and histopathological endpoints to build a comprehensive picture of hepatoprotection. The principal testing items are listed below.

Primary Biochemical Indicators

• Serum alanine aminotransferase (ALT/GPT) activity — the most sensitive marker of hepatocellular injury
• Serum aspartate aminotransferase (AST/GOT) activity — reflects both hepatic and mitochondrial damage
• Liver index (liver-to-body weight ratio) — indicates organ swelling or hypertrophy following toxic insult

Histopathological Examination

• Hematoxylin and eosin (H&E) staining of liver sections for morphological assessment
• Evaluation of hepatocyte degeneration, necrosis, inflammatory cell infiltration, steatosis, and lobular architecture disruption
• Semi-quantitative scoring by qualified veterinary pathologists comparing treated groups against the injury model group

Supplementary Oxidative Stress and Lipid Markers

• Hepatic malondialdehyde (MDA) content — a lipid peroxidation product reflecting oxidative liver damage
• Reduced glutathione (GSH) levels — an endogenous antioxidant defense indicator
• Superoxide dismutase (SOD) activity in liver tissue
• Hepatic triglyceride content — particularly relevant for alcohol-associated injury models with steatotic features

Testing Methods

The study follows a controlled parallel-group design using healthy SPF-grade mice or rats, with randomization and blinded endpoint assessment to minimize bias.

Experimental Design

• Animal species: healthy adult mice (commonly 18–22 g) or rats, with equal sex distribution or single-sex grouping as justified by the protocol
• Group allocation: blank control group (no injury induction), injury model control group (hepatotoxin only), and at least three dose groups of the test sample receiving the hepatotoxin concurrently
• Dose setting: doses are typically derived from the recommended human intake, converted to animal equivalents (often 5, 10, and 30 times the human dose on a body-weight basis)
• Administration route: oral gavage or dietary admixture, generally for 30 consecutive days; the maximum volume and concentration are constrained by animal welfare and formulation limits

Liver Injury Models

Depending on the intended product positioning, one of several chemical injury models may be selected:

• Carbon tetrachloride (CCl4) model: a single intraperitoneal or subcutaneous dose of diluted CCl4 induces acute hepatocellular necrosis; this is the classic model for general chemical liver injury evaluation
• Alcohol (ethanol) model: acute high-dose or subacute repeated ethanol administration reproduces alcohol-associated liver injury with elevated transaminases and steatosis, suitable for products targeting alcohol-related liver stress
• D-galactosamine (D-GalN) model: induces diffuse hepatocellular injury resembling viral-like hepatitis morphology, used when a metabolic-type injury profile is desired

Endpoint Collection and Analysis

• Blood is collected at the scheduled terminal time point (commonly 16–24 hours after the final hepatotoxin challenge) for serum ALT and AST determination using validated enzymatic assay kits
• Animals are weighed and euthanized humanely; livers are excised, weighed for liver index calculation, and fixed in neutral buffered formalin for histology
• Statistical analysis compares the model group against the blank group to confirm successful injury induction, and compares each dose group against the model group using appropriate tests (ANOVA with post-hoc comparison or non-parametric equivalents)

Result Judgment Criteria

• Model validity: the injury model group must show a statistically significant elevation in ALT and/or AST compared with the blank control group, accompanied by confirmatory histopathological lesions
• Protective effect: the test sample is judged positive if at least one dose group shows a statistically significant reduction in injury markers compared with the model group, with a discernible dose-response relationship and histopathological improvement
• A positive conclusion generally requires concordance between biochemical results and pathological findings, not transaminase reduction alone
• The study is repeated or extended if results are inconsistent between sexes, between dose levels, or between the two endpoints

Applications

Protective function testing against chemical liver injury serves multiple practical purposes across the product lifecycle:

• Regulatory registration and filing: providing the functional evidence package required for health food "blue hat" registration or record-filing submissions in markets where liver protection claims are regulated
• Claim substantiation: supporting labeling and advertising statements with scientifically defensible data, reducing the risk of non-compliant marketing claims
• Research and development: screening candidate formulas, comparing ingredient sources, optimizing dosage levels, and verifying whether formulation changes preserve efficacy
• Quality consistency verification: demonstrating that commercial-scale batches retain the functional potency established during development
• Market access support: supplying technical dossiers for distributors, e-commerce platforms, and international buyers who request functional verification of hepatoprotective products
• Scientific publication: generating data suitable for peer-reviewed studies supporting brand credibility and consumer education

FAQ

What standards govern this test?

The evaluation is primarily based on the Technical Standards for Testing and Assessment of Health Food (2003 Edition) for the functional claim "protection against chemical liver injury," supported by the GB 15193 series for toxicological testing principles, animal care, and laboratory methodology. Test facilities should operate under ISO/IEC 17025 accreditation.

How long does the evaluation take?

A typical study includes an acclimatization period, a 30-day sample administration phase, injury induction, and terminal sample analysis. Including histopathology and report compilation, the complete evaluation cycle generally ranges from six to ten weeks, depending on the model and laboratory scheduling.

Is animal testing the only accepted approach?

For registration-grade functional substantiation of liver protection claims in regulated markets, the animal model remains the primary accepted method because it integrates absorption, metabolism, and tissue-level response. Complementary in vitro assays (for example, CCl4- or ethanol-treated hepatocyte lines) are valuable for screening but are not yet accepted as standalone evidence for official health function claims.

How much sample is needed for testing?

Sample requirements depend on the dosage form, dose levels, group sizes, and study duration. As a practical rule, sponsors should provide enough finished product to deliver the highest animal dose for 30 days across all dose groups, typically several hundred grams to a few kilograms of finished product or the equivalent concentrate, plus reserve stock for repeat preparations.

What constitutes a positive (protective) result?

A positive result requires that the model group demonstrates significant liver injury versus blank controls, and that at least one test-dose group shows a statistically significant amelioration of ALT/AST elevation with corroborating histopathological improvement, ideally exhibiting a dose-response trend. Biochemical improvement without pathological confirmation is generally insufficient for a positive conclusion.

Can a product claim liver protection without this test?

In jurisdictions regulating health function claims, marketing a product as protective against chemical liver injury without substantive functional evidence exposes the manufacturer to regulatory enforcement and advertising liability. Independent testing through accredited third-party laboratories provides the documented basis needed for lawful claim use and consumer confidence.